About CytunePharma
CytunePharma is a company based in Nantes (France) founded in 2007 was acquired by Sotio in August 2018. CytunePharma has raised $7.84 million across 3 funding rounds from investors including SOTIO, PPF Group and Starquest Capital. CytunePharma operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Nantes, France
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of CytunePharma
CytunePharma has successfully raised a total of $7.84M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $6.6 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CytunePharma
CytunePharma has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include SOTIO, PPF Group and Starquest Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PPF Group is engaged in international investment across diverse sectors.
|
Locked | Locked | Locked | |
|
Investments in Europe and US are made by Starquest Capital.
|
Locked | Locked | Locked | |
|
Activated dendritic cells are developed for cancer immunotherapy treatments.
|
Locked | Locked | Locked |
Investor details for CytunePharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CytunePharma
Investment portfolio details for CytunePharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CytunePharma
Detailed financials for CytunePharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cytunepharma Comparisons
Peer comparison for CytunePharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CytunePharma
CytunePharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of CytunePharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cytunepharma
Complete news archive for CytunePharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CytunePharma
CytunePharma was founded in 2007 and raised its 1st funding round 5 years after it was founded.
CytunePharma is headquartered in Nantes, France. It is registered at Nantes, Pays De La Loire, France.
CytunePharma is a funded company, having raised a total of $7.84M across 3 funding rounds to date.
Cytune Pharma is focussed on developing immunotherapies for cancer. It is developing therapies based on the reset, restore and activation of the antitumor immune system. Its lead product CYP0150 is a recombinant protein consisting of a human IL-15 linked to the Sushi domain of the human alpha chain receptor which stimulates natural killer and cytotoxic cells, without activating regulatory T cells that dampen the immune response. The candidate along with other immunotherapy strategies, such as checkpoint inhibitors claims to have shown effective and is currently in preclinical trials. It is planning to enter phase 1 trials in 2017. It is also developing conjugated monoclonal antibodies linked to CYP 0150.
CytunePharma's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
CytunePharma has 3 investors. Key investors include SOTIO, PPF Group, and Starquest Capital.